Table 2.
Characteristics of studies on inactivated vaccines
| Author (year of publication) | Location | Age of study population | Study design | Type of vaccine |
|---|---|---|---|---|
| Beutner (1979) |
USA |
7-14 years |
RCT |
Inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (X-41). |
| Clover (1991) |
USA |
3-18 years |
RCT |
Inactivated trivalent vaccine containing A/Chile/83 (H1N1), A/Mississippi/85 (H3N2) and B/Ann Arbor/86 |
| Colombo (2001) |
Italy |
1-6 years |
RCT |
Inactivated trivalent subvirion vaccine containing A/Johannesburg/33/94-like, A/Singapore/6/86-like and B/Beijing/184/93-like. |
| Cowling (2010) |
Hong Kong, Kowloon |
6-15 years |
RCT |
Inactivated TIV seasonal vaccine containing strains A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007(H3N2)-like and B/Florida/4/2006. |
| Gruber (1990) |
USA |
3-18 years |
RCT |
Inactivated TIV containing A/Chile/83 (H1N1), A/Philippines/82 (H3N2) and B/USSR/83 strains. |
| Hoberman (2003) |
USA |
6-24 months |
RCT |
Inactivated trivalent subvirion influenza vaccine in 1999-200, containing: A/Beijing/262/95 (H1N1), A/Sydney/15/97 (H3N2) and B/Yamanashi/166/98 and in 2000-01: A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 |
| Khan (1996) |
Russia |
9-12 years |
RCT |
Inactivated, trivalent split-virus influenza vaccine containing A/Taiwan/1/86 (H1N1), A/Shanghai/16/89 (H3N2) and B/Yamagata/16/88 |
| Maeda (2004) |
Japan |
6-24 months |
RCT |
Inactivated influenza vaccine containing, in 1999-2000: A/Beijing/262/95 H1N1), A/Sydney/5/97 (H3N2) and B/Shandong/7/97. In 2000-01: A/New Caledonia/20/99, A/Panama/2007/99 and B/Johannesburg/5/99. In 2001-02: A/New Caledonia/20/99, A/Panama/2007/99 and B/Johannesburg/5/99 |
| Principi (2003) |
Italy |
0.5-5 years |
RCT |
Inactivated virosomal influenza vaccine (no information on strains included) |
| Rudenko (1993) |
Russia |
7-14 years |
RCT |
Inactivated (strains contained are the same as in the live vaccine, detailed above). |
| Vesikari (2011) |
Germany, Finland |
6 to <72 months |
RCT |
Inactivated, TIV containing, in 2007-08: A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 and in 2008-09: A/Brisbane/59/2007, A/Brisbane/10/2007 and B/Florida/4/2006 and TIV MF59 emulsion adjuvant |
| Fujieda (2008) |
Japan |
Under 6 years |
Cohort study |
Inactivated TIV containing A/New Caledonia/20/99 (H1N1), A/Panama/2007/99(H3N2) and B/Shandong/7/97. |
| Heikkinen (1991) |
Finland |
1-3 years |
Cohort study |
Inactivated, trivalent subvirion influenza vaccine containing A/Taiwan/1/86 (H1N1), A/Sichuan/2/87 (H3N2) and B/Victoria/2/87. |
| Katayose (2011) |
Japan |
0.5-5 years |
Cohort study |
Inactivated TIV - vaccine components were decided yearly, by National Institute of Infectious Diseases, Japan based on WHO recommendations |
| Salleras (2006) |
Spain |
3-14 years |
Cohort study |
Inactivated virosomal subunit influenza vaccine (no further details) |
| Yamaguchi (2010) |
Japan |
6-12 years |
Cohort study |
Inactivated trivalent influenza vaccine containing A/New Caledonia/20/99 (H1N1), A/Hiroshima/52/2005 (H3N2) and B/Malaysia/2506/2004 |
| Joshi (2009) |
USA |
6-59 months |
Case-control |
Inactivated trivalent influenza vaccine strains contained over the 8-year study period varied according to ACIP recommendations |
| Kelly (2011) | Australia, Western Australia | 0.5-5 years | Case-control | Inactivated trivalent influenza vaccine containing A/Solomon Islands/3/2006 (H1N1)-like strain, an A/Brisbane/10/2007 (H3N2)-like strain and B/Florida/4/2006-like strain |